RT Journal Article
SR Electronic
T1 Development and evaluation of a new IgM/IgG rapid diagnostic test for SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.09.20209866
DO 10.1101/2020.10.09.20209866
A1 Ducrest, P.J.
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.09.20209866.abstract
AB There is an urgent need in rapid diagnostic test (RDT) to detect antibodies against SARS-CoV-2. We have developed a rapid and simple point-of-care lateral flow immunoassay (LFIA) detecting IgM and IgG against SARS-CoV-2 in 10 minutes. The aim of this study is to evaluate the diagnostic performance of this RDT. RT-PCR positive plasma samples (n=35) for SARS-CoV-2 and 97 negative control samples were studied. Diagnostic performance of IgG/IgM RDT was assessed using both gold standard RT-PCR and Electro-chemiluminescence immunoassay (ECLIA) Elecsys® Anti-SARS-CoV-2 total Ig. Overall, RDT sensitivity was 100% (95% confidence interval [95%CI]: 88-100%) and specificity 93% (95% CI: 85-97%). This IgG/IgM RDT done in plasma displays a high diagnostic accuracy for SARS-CoV-2 IgG/IgM in high COVID-19 prevalence settings. Its use could be considered in the absence of routine diagnostic serology facilities for samples collected between 10 and 180 days after symptoms onset.Competing Interest StatementPJD is the CEO of GaDia SA, the developer and manufacturer of this RDT.Clinical TrialThis study was evaluated by the Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests with foreign leftover samples.Funding StatementThis study was funded by GaDia SA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was evaluated by the Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests with foreign leftover samples. All necessary patient/participant consent has been obtained by the supplier of the samples.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available in Supplementary Material